Table 1.
Clinical characteristics of the two groups
| Characteristics | No. of patients (%) | P | ||
|---|---|---|---|---|
| Total (n = 118) |
NPF group (n = 58) |
DPF group (n = 60) |
||
| Median age (range) | 44(22–68) | 43(22–65) | 45(22–68) | 0.214 |
| Gender | ||||
| Males | 98(83.1) | 47(81.0) | 51(85.0) | 0.371 |
| Females | 20(16.9) | 11(19.0) | 9(15.0) | |
| Clinical stage (China, 2008) | ||||
| III | 66(55.9) | 34(58.6) | 32(53.3) | 0.347 |
| IVa | 52(44.1) | 24(41.4) | 28(46.7) | |
| T stage | 0.436 | |||
| T1 | 6(5.1) | 3(5.1) | 3(5.0) | |
| T2 | 20(16.9) | 12(20.7) | 8(13.3) | |
| T3 | 57(48.3) | 27(46.6) | 30(50.0) | |
| T4 | 35(29.7) | 16(27.6) | 19(31.7) | |
| N stage | 0.585 | |||
| N0 | 3(25.4) | 2(3.4) | 1(1.6) | |
| N1 | 27(22.9) | 15(25.9) | 12(20.0) | |
| N2 | 67(56.9) | 30(51.7) | 37(61.7) | |
| N3 | 21(17.8) | 11(19.0) | 10(16.7) | |